Literature DB >> 20534697

IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.

Mindaugas Andrulis, David Capper, Jochen Meyer, Roland Penzel, Christian Hartmann, Hanswalter Zentgraf, Andreas von Deimling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20534697      PMCID： PMC2948109          DOI： 10.3324/haematol.2010.024430

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors:  Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

Authors:  Wen-Chien Chou; Hsin-An Hou; Chien-Yuan Chen; Jih-Luh Tang; Ming Yao; Woei Tsay; Bor-Shen Ko; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yen-Ning Huang; Yi-Chang Chang; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2010-01-22       Impact factor: 22.113

6.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

7.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Authors:  Omar Abdel-Wahab; Taghi Manshouri; Jay Patel; Kelly Harris; Jinjuan Yao; Cyrus Hedvat; Adriana Heguy; Carlos Bueso-Ramos; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

8.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

10.  Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

Authors:  Anthony Green; Philip Beer
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 176.079
View more
  4 in total

Review 1.  [Predictive molecular pathological stratification of hematological neoplasms].

Authors:  M Andrulis
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

2.  IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2010-10       Impact factor: 11.047

3.  Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.

Authors:  Keyur P Patel; Bedia A Barkoh; Zhao Chen; Deqin Ma; Neelima Reddy; L Jeffrey Medeiros; Rajyalakshmi Luthra
Journal:  J Mol Diagn       Date:  2011-09-01       Impact factor: 5.341

4.  Newly Identified Characteristics and Suggestions for Diagnosis and Treatment of Diffuse Leptomeningeal Glioneuronal/Neuroepithelial Tumors: A Case Report and Review of the Literature.

Authors:  Megan R Lyle; Jaydevsinh N Dolia; Jonathan Fratkin; Todd A Nichols; Betty L Herrington
Journal:  Child Neurol Open       Date:  2015-02-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.